Credit Suisse’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-167,800
| Closed | -$12.2M | – | 3882 |
|
|
2021
Q4 | $12.2M | Sell |
167,800
-40,300
| -19% | -$2.78M | 0.01% | 1357 |
|
|
2021
Q3 | $14.5M | Buy |
208,100
+126,600
| +155% | +$8.89M | 0.01% | 1279 |
|
|
2021
Q2 | $5.61M | Buy |
81,500
+26,100
| +47% | +$1.74M | ﹤0.01% | 1988 |
|
|
2021
Q1 | $3.58M | Sell |
55,400
-455,800
| -89% | -$29.4M | ﹤0.01% | 2352 |
|
|
2020
Q4 | $29.8M | Buy |
511,200
+314,500
| +160% | +$19M | 0.01% | 959 |
|
|
2020
Q3 | $12.4M | Sell |
196,700
-2,800
| -1% | -$194K | 0.01% | 1250 |
|
|
2020
Q2 | $15.3M | Sell |
199,500
-270,500
| -58% | -$20.7M | 0.01% | 1083 |
|
|
2020
Q1 | $35.1M | Buy |
470,000
+157,000
| +50% | +$10.8M | 0.03% | 563 |
|
|
2019
Q4 | $20.3M | Buy |
313,000
+48,000
| +18% | +$3.13M | 0.01% | 1009 |
|
|
2019
Q3 | $16.8M | Buy |
265,000
+29,200
| +12% | +$1.91M | 0.01% | 1021 |
|
|
2019
Q2 | $15.9M | Buy |
235,800
+45,900
| +24% | +$3.02M | 0.01% | 1050 |
|
|
2019
Q1 | $12.3M | Sell |
189,900
-304,000
| -62% | -$20.2M | 0.01% | 1120 |
|
|
2018
Q4 | $30.9M | Buy |
493,900
+268,900
| +120% | +$18.8M | 0.03% | 568 |
|
|
2018
Q3 | $17.4M | Sell |
225,000
-369,500
| -62% | -$27.9M | 0.02% | 956 |
|
|
2018
Q2 | $42.1M | Buy |
594,500
+306,900
| +107% | +$21.7M | 0.04% | 454 |
|
|
2018
Q1 | $21.7M | Sell |
287,600
-392,400
| -58% | -$31.2M | 0.02% | 811 |
|
|
2017
Q4 | $48.7M | Sell |
680,000
-207,500
| -23% | -$15.8M | 0.04% | 433 |
|
|
2017
Q3 | $71.9M | Buy |
887,500
+142,500
| +19% | +$10.9M | 0.07% | 296 |
|
|
2017
Q2 | $52.7M | Sell |
745,000
-295,800
| -28% | -$19.7M | 0.05% | 392 |
|
|
2017
Q1 | $70.7M | Buy |
1,040,800
+650,300
| +167% | +$45.7M | 0.06% | 318 |
|
|
2016
Q4 | $28M | Sell |
390,500
-400
| -0.1% | -$29.7K | 0.03% | 638 |
|
|
2016
Q3 | $30.9M | Buy |
390,900
+220,700
| +130% | +$17.9M | 0.03% | 642 |
|
|
2016
Q2 | $14.2M | Buy |
170,200
+70,000
| +70% | +$6.21M | 0.02% | 955 |
|
|
2016
Q1 | $9.2M | Buy |
+100,200
| New | +$9.04M | 0.01% | 1159 |
|
|
2015
Q3 | – | Sell |
-266,000
| Closed | -$31.1M | – | 4344 |
|
|
2015
Q2 | $31.1M | Buy |
266,000
+235,800
| +781% | +$25.8M | 0.03% | 609 |
|
|
2015
Q1 | $2.96M | Sell |
30,200
-74,800
| -71% | -$7.6M | ﹤0.01% | 2071 |
|
|
2014
Q4 | $9.9M | Sell |
105,000
-25,000
| -19% | -$2.59M | 0.01% | 1288 |
|
|
2014
Q3 | $13.8M | Sell |
130,000
-16,000
| -11% | -$1.57M | 0.01% | 1113 |
|
|
2014
Q2 | $12.1M | Buy |
+146,000
| New | +$11.4M | 0.01% | 1255 |
|
|
2014
Q1 | – | Sell |
-150,100
| Closed | -$11.3M | – | 4728 |
|
|
2013
Q4 | $11.3M | Hold |
150,100
| – | – | 0.01% | 1179 |
|
|
2013
Q3 | $9.44M | Buy |
150,100
+100
| +0.1% | +$5.98K | 0.01% | 1178 |
|
|
2013
Q2 | $7.69M | Buy |
+150,000
| New | +$7.82M | 0.01% | 1298 |
|
Other funds holding GILD
Credit Suisse's GILD Position: Q1 2024 in Review
Credit Suisse reduced its Gilead Sciences (GILD) stake by 6.6% in Q1 2024, selling an estimated $15.8M and leaving 2,888,499 shares worth $212M. The position accounts for 0.2% of the portfolio, ranked #87.
Credit Suisse first reported a position in GILD in Q2 2013 and has held it in 44 quarters since. The position peaked at $705M in Q2 2015. 1,722 funds tracked by Wall St. Rank hold GILD as of Q1 2024.
- Credit Suisse held 2,888,499 shares of Gilead Sciences worth $212M as of Q1 2024.
- Credit Suisse sold 205,129 Gilead Sciences shares in Q1 2024, an estimated $15.8M.
- Gilead Sciences made up 0.2% of Credit Suisse's portfolio in Q1 2024, its #87 holding.
- Credit Suisse first reported a position in Gilead Sciences in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Gilead Sciences position peaked at $705M in Q2 2015.
- 1,722 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.